



Note from the Sponsor: cancelled (or early terminated) trial

Sponsor name:	Janssen Research & Development, LLC
EudraCT number:	2022-001442-38
Protocol number:	64407564MMY3008
Clinical trial title:	A Phase 3 Study Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma who have Received at least 4 Prior Therapies Including an Immunomodulatory Drug, a Proteasome Inhibitor, and an Anti-CD38 Antibody
Reasons for the Cancellation (or early termination):	Janssen made the decision to terminate the study due to emerging data that the confirmatory, randomized Blenrep DREAMM-3 (Blenrep vs. Pom-dex in RRMM patients with >2 prior lines) trial that did not meet its primary PFS endpoint.